MedPath

Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure

Phase 2
Completed
Conditions
Menopause
Hormone Antagonist
Breast Cancer
Estrogen Receptor Positive Tumor
Interventions
Drug: Immune-attractant
Drug: Durvalumab
Procedure: Biopsy
Registration Number
NCT02997995
Lead Sponsor
UNICANCER
Brief Summary

This is an open-label, multicentric, international, phase II trial testing aromatase inhibitors in combination with durvalumab in patients with CD8+ T cell infiltration (\>10% CD8+ T cells in the tumor). The trial includes two sequences: The first part of the treatment will consist in 4-6 weeks treatment with immune-attractants; in the second part, CD8+ patients will receive 6 months of durvalumab combined with exemestane.

Detailed Description

The study is conducted in 2 parts:

Part 1: lymphocyte attraction. After the screening phase, the patient will receive immune-attractant combined with exemestane for six weeks.

As immune-attractants are added over the course of the study, they will appear as subsequent appendices in the full protocol.

Up to 4 cohorts may be tested sequentially in this design until up to 240 evaluable patients have been treated.

The first cohort of patients will receive tremelimumab (3 mg/kg, single infusion) combined with exemestane (25 mg daily). In each cohort, an interim analysis will be performed after 30 patients in order to potentially stop the cohort (if less than 25% of patients present \>10% CD8+ cells in the tumor after 3 weeks). If all 4 cohorts are closed and the target number of 56 patients for part 2 has not been reached, additional patients will be recruited and treated with the best performing immune-attractant treatment based on the part I results. From the moment 56 patients are included in part 2, no more patients will be entered in part 1.

After three weeks (+/- 3 days), a tumor biopsy will be done. Patients who present \>10% CD8+ cells in the tumor after 3 weeks and remain eligible will be included in the second part of the trial (patients who do not present CD8+ T cells on the 3-week biopsy will be treated at the investigator's choice).

Part 2: lymphocyte activation (anti-PD1 treatment) Four to six weeks after immune-attractant start, patients having \>10% CD8+ cells in the tumor will receive durvalumab 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months.

Part 2 will include two steps. In the first step, we will include 23 patients. If 2 or more pathological complete responses are observed in these 23 patients, the part 2 will move to step 2. 33 additional patients will be included in the step 2.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
61
Inclusion Criteria

  1. Age ≥18 years post-menopausal according to one of the following criteria:

    • Age >60 years
    • Or Bilateral ovariectomy
    • Or Age ≤60, with an uterus and presenting an amenorrhea of more than 12 months and FSH and estradiol in the postmenopausal range
    • Or Age ≤60, without an uterus and FSH and estradiol in the postmenopausal range

  2. Histologically proven invasive breast cancer eligible to neoadjuvant endocrine therapy according to multidisciplinary tumor board.

    Note: Multicentric/multifocal tumors are allowed if all share the same characteristics

  3. cT2-T4, any N; cT2 are eligible only if the clinical tumor size is >3 cm

  4. Non metastatic, M0 (according to clinical staging)

  5. Luminal A patients ER-positive by immunohistochemistry (IHC) according to the following criteria (local assessment): Grade I or II AND ER-positive (≥60%) AND Ki67 <20%

  6. Her2-negative by IHC (score 0 or 1+) and/or fluorescent in situ hybridization (FISH)/chromogenic in situ hybridization (CISH) negative according to local assessment

  7. CD8+ T Cell infiltration defined as >10% cells stained with anti-CD8 monoclonal antibody by IHC at the 3-week biopsy (applicable for inclusion in part 2 only)

  8. Available tumor samples from baseline biopsy

  9. World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrolment

  10. Adequate organ and marrow function as defined below:

    • Hemoglobin ≥9.0 g/dL
    • Absolute neutrophil count ≥1.5 × 10⁹/L
    • Platelet count ≥100 × 10⁹/L
    • Serum bilirubin ≤1.5 × upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert's syndrome, who will be allowed in consultation with their physician
    • Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤2.5 × ULN
    • Adequate renal function as determined by CKD-EPI formula (using actual body weight)

  11. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures

  12. Written informed consent obtained prior to performing any protocol-related procedures, including screening evaluations

Read More
Exclusion Criteria

  1. Inflammatory breast cancer

  2. No prior exposure to immune-mediated therapy including, but not limited to, other anti-CTLA-4, anti-PD-1, anti-PD-L1, and anti-programmed cell death ligand 2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines

  3. Any concurrent chemotherapy, investigational product (IP), biologic therapy for cancer treatment

  4. Previous Radiotherapy treatment to more than 30% of the bone marrow;

  5. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose

  6. History of allogenic organ transplantation

  7. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis with the exception of diverticulosis, celiac disease or other serious gastrointestinal chronic conditions associated with diarrhea), systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome (granulomatosis with polyangiitis), Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc within the past 3 years prior to the start of treatment. The following are exceptions to this criterion:

    • Patients with vitiligo or alopecia
    • Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement or psoriasis not requiring systemic treatment

  8. Any condition that, in the opinion of the Investigator, would interfere with the evaluation of investigational product or interpretation of patient safety or study results, including ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events from investigational products, or compromise the ability of the patient to give written informed consent

  9. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms

  10. History of active primary immunodeficiency

  11. Known history of active tuberculosis

  12. Active infection including hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)

  13. Current or prior use of immunosuppressive medication within 14 days before the first dose. The following are exceptions to this criterion:

    • Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection)
    • Systemic corticosteroids at physiologic doses not exceeding 10 mg/day of prednisone or its equivalent
    • Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)

  14. Receipt of live, attenuated vaccine within 30 days prior to the first dose of IP.

    Note: Patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of IP

  15. Known allergy or hypersensitivity to any medicinal product used in the trial or any excipient

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Immune-attractant/lymphocyte activationImmune-attractantAfter the screening phase, the patient will receive immune-attractant combined with exemestane for six weeks. After three weeks (+/- 3 days), a tumor biopsy will be done. Patients who present \>10% CD8+ cells in the tumor after 3 weeks and remain eligible will be included in the second part of the trial i.e. lymphocyte activation. In this second part, patients will receive durvalumab 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months. The pathological response will be checked by surgery.
Immune-attractant/lymphocyte activationBiopsyAfter the screening phase, the patient will receive immune-attractant combined with exemestane for six weeks. After three weeks (+/- 3 days), a tumor biopsy will be done. Patients who present \>10% CD8+ cells in the tumor after 3 weeks and remain eligible will be included in the second part of the trial i.e. lymphocyte activation. In this second part, patients will receive durvalumab 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months. The pathological response will be checked by surgery.
Immune-attractant/lymphocyte activationDurvalumabAfter the screening phase, the patient will receive immune-attractant combined with exemestane for six weeks. After three weeks (+/- 3 days), a tumor biopsy will be done. Patients who present \>10% CD8+ cells in the tumor after 3 weeks and remain eligible will be included in the second part of the trial i.e. lymphocyte activation. In this second part, patients will receive durvalumab 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months. The pathological response will be checked by surgery.
Primary Outcome Measures
NameTimeMethod
pathological Complete Responseat time of surgery

Response at surgery

Secondary Outcome Measures
NameTimeMethod
Assessment of Ki67at surgery

measure of Ki67

Predictive value of PDL1 expression for the efficacy of Durvalumabon baseline biopsy and biopsy at 3 weeks

correlate Immune infiltrate intensity with the proportion of tumor cells expressing PD-L1 by Ventana SP263 assay

Clinical responseafter 6 months of Durvalumab

Clinical exam

Toxicities1 year and 8 months

Common terminology criteria for adverse events (CTC-AE) v4.03

Predictive value of Mutational load for efficacy of Durvalumabon baseline biopsy and blood samples

exome sequencing on baseline samples

Number of CD8+ T cellat biopsy (3 weeks)

exam at biopsy and comparison between biopsy and Baseline biopsy rates

Trial Locations

Locations (29)

HU Arnau de Vilanova

🇪🇸

Lleida, Spain

Centre François Baclesse

🇫🇷

Caen, France

Institut Jean Godinot

🇫🇷

Reims, France

Centre Léon Bérard

🇫🇷

Lyon, France

Centre Hospitalier de Cahors

🇫🇷

Cahors, France

Centre George François Leclerc

🇫🇷

Dijon, France

Institut Daniel Hollard Groupe Hôspitalier

🇫🇷

Grenoble, France

HU Ramon y Cajal

🇪🇸

Madrid, Spain

Institut Curie Site Paris

🇫🇷

Paris, France

Centre Hospitalier cote Basque

🇫🇷

Bayonne, France

Centre Hôspitalier de Cholet

🇫🇷

Cholet, France

HU Vall Hebron

🇪🇸

Barcelona, Spain

Centre Hospitalier Bretagne Sud

🇫🇷

Lorient, France

CHU Bretonneau - Centre Henry Kaplan

🇫🇷

Tours, France

Hospital Clinic Barcelona

🇪🇸

Barcelona, Spain

Institut Bergonié

🇫🇷

Bordeaux, France

ICO Badalona

🇪🇸

Badalona, Spain

Sahlgrenska University Hospital

🇸🇪

Gothenburg, Sweden

Centre Oscar Lambret

🇫🇷

Lille, France

CHU Limoges

🇫🇷

Limoges, France

Hôpital Saint Louis APHP

🇫🇷

Paris, France

Institut Claudius Regaud

🇫🇷

Toulouse, France

Centre Hospitalier Perpignan

🇫🇷

Perpignan, France

Institut Curie Hôpital René Huguenin

🇫🇷

Saint Cloud, France

Centre Paul Strauss

🇫🇷

Strasbourg, France

Gustave Roussy

🇫🇷

Villejuif, France

Institut Paoli Calmettes

🇫🇷

Marseille, France

Hospital Clínico Universitario de Valencia

🇪🇸

Valencia, Spain

CIO Clara Campal

🇪🇸

Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy